Miscellaneous Pictures/iStock Editorial through Getty Pictures
Abbott (NYSE:ABT) introduced that the U.S. Meals and Drug Administration has accepted two new over-the-counter steady glucose monitoring methods – Lingo and Libre Rio – primarily based on the corporate’s FreeStyle Libre steady glucose monitoring expertise.
The corporate mentioned its customers Lingo, a bio-wearable system, is designed for normal customers who need to enhance their total well being.
Libre Rio, then again, is designed for adults with kind 2 diabetes who do not take insulin and usually handle their diabetes by way of life modifications.
This follows the FDA’s approval in March of Dexcom’s Stelo, the primary accepted over-the-counter steady glucose monitor.
Dexcom (DXCM) shares have been down barely in pre-market buying and selling, whereas ABT shares have been up barely.
Extra details about Abbott Laboratories
